We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oxford Biodynamics Plc | OBD | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.40 | 08:00:28 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.40 | 0.40 | 0.40 | 0.40 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 14/5/2025 07:41 by maverick247 5 reasons to add OBD to your watch list https://smallcappix. |
Posted at 13/3/2025 08:05 by kingston78 13 March 2025Oxford BioDynamics ("OBD" or the "Company" and, together with its subsidiaries, the "Group") Bupa UK insurance to cover Oxford BioDynamics' EpiSwitch® PSE prostate cancer test · Bupa UK insurance customers with a raised PSA level and no additional high risk factors or symptoms will now be covered for PSE, a smart blood test which accurately predicts the presence or absence of prostate cancer · Expansion of OBD/Bupa UK insurance partnership beyond existing coverage of CiRT significantly enhances access to PSE in the UK · Coverage for both OBD's PSE and CiRT3 tests reflects Bupa's commitment to leveraging advanced precision medicine testing to transform cancer care Oxford, UK - 13 March 2025 - Oxford BioDynamics Plc (AIM: OBD), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, and Bupa announce an expanded strategic agreement to give its health insurance customers access to OBD's EpiSwitch PSE prostate cancer detection test. Bupa is a leading health insurer in the UK with around 3.9m customers. Robin Clark, Medical Director for Bupa Insurance, said: "We're pleased to partner with Oxford BioDynamics to cover the advanced EpiSwitch PSE test. The PSE provides a more accurate path to diagnosing prostate cancer, where getting an early diagnosis can make the disease nearly completely survivable. Offering the PSE and CiRT tests reflects our commitment to leverage the most advanced precision medicine testing to provide doctors with the tools they need to make informed decisions." Under this new agreement, the PSE test will be funded for Bupa health insurance customers with a raised prostate-specific antigen level and no additional high-risk factors or urinary symptoms. The EpiSwitch PSE is OBD's validated, rapid, highly accurate blood test for prostate cancer (accuracy 94%, specificity 97%, sensitivity 86%)1, significantly boosting the accuracy of PSA alone. Crucially, the positive predictive value (PPV) of PSE is 93%, compared to just 25% for PSA. PSA's low PPV is one of the main arguments against using it as a population-wide screening test. About 25% of men with a raised PSA will go on to be diagnosed with prostate cancer. With the PSE, more than 9 out of every 10 men who receive a positive "high likelihood" PSE will go on to have a confirmatory biopsy1. This level of performance can reduce the total number of men who do not have prostate cancer being referred for unnecessary MRI scans and invasive biopsies2. These clinical results are supported by an accumulation of real-world evidence related to the clinical utility. Iain Ross, Executive Chairman of OBD, said: "Joining forces with a pioneering healthcare insurer like Bupa ensures that more men have access to an accurate diagnosis by using the EpiSwitch PSE test. Prostate Cancer is the most common cancer in men in the UK, and yet there is currently no nationwide screening programme due to limitations of current testing modalities. With its high accuracy and PPV, EpiSwitch PSE can be integrated into existing pathways to more precisely direct individuals toward further expensive and invasive diagnostics and treatments. We remain focused on forging strategic partnerships to build on this momentum and continue to drive value." |
Posted at 10/3/2025 14:29 by london07 www.bbc.com/news/artOBD sat on a goldmine! Serious questions being asked by leaders in the field with regards to PSA tests, OBD tests are superior and they are desperately needed. Prostate cancer is the fastest growing cancer worldwide. When this takes off, there will be no stopping. DYOR |
Posted at 27/2/2025 12:55 by bri15 Market looks forward not back,the results should be very positive as far as the future is concerned,the past has gone,OBD going to grow into a fantastic company,this is one of the very few AIM companies which are worth a long term investment and not a five minute trade. |
Posted at 27/2/2025 09:39 by maverick247 The results imo will not likely amaze but that's not the investment thesis here right now - it's about the turnaround and Iain getting the partners Rishi sunak at the OBD labs is interesting given the company are now engaged with the nhs |
Posted at 21/2/2025 11:21 by kingston78 Every dog has its days, such as VAST which sank to 0.07 p. I believed in its survival and revival, and indeed it has, as recently it has risen to over 0.2 p. That is how one makes good profit.OBD is financially secured. It has a new CEO. It has a portfolio of valuable products/IP. Everyone should buy shares in this company for at least double your money in a short space of time. |
Posted at 17/2/2025 10:22 by anitabruzzese0 We’re thrilled to partner with Regina Maria, Romania’s largest private healthcare provider, serving 5 million patients.Regina Maria will integrate our EpiSwitch® PSE and CiRT tests into its oncology portfolio, expanding access to PSE and CiRT tests for physicians and patients across the country. Learn more: obdx.co/yke. #OBD #EpiSwitch #Oncology #PrecisionMedicine Latest post on X Massive news |
Posted at 14/2/2025 11:11 by edwardhimmers1977 Reddit Rumour @ OBDA leaked email on Reddit showing communication between OBDs CEO Ross, & the Romanian Health minister. The emails reveal 3 more contracts have been signed in Romania. It also confirms 2 new contracts in Spain have also been lined up.... The 3 Romanian contracts will be announced early next week. The news of how big the RNS regarding OBDs cancer test success, seems to have been overlooked by the markets. In the RNS the CEO states; ▪︎"Disc He gives that massive "nod" to the market in the 5th RNS!! RNS from 05/02 [3 main highlights] ▪︎ Results of multi-institutional clinical study published in peerx reviewed journal 'Cancers' confirms efficacy of Oxford BioDynamics' EpiSwitch® blood-based Colorectal No-Stool Test (NST) ▪︎ High accuracy of detection reported at 81% for early cancer stages and 82% for non-cancerous polyps ▪︎ Discussions are underway with potential partners to bring this potentially evolutionary test to clinical practice 12/02 RNS; "Oxford BioDynamics partners with Regina Maria to offer EpiSwitch clinical tests in Romania Regina Maria is Romania's largest private healthcare provider, serving 5 million patients OBD's EpiSwitch PSE and CiRT tests will be available to physicians and patients in Romania as part of Regina Maria's oncology portfolio" |
Posted at 05/2/2025 19:21 by anitabruzzese0 New X Post from OBD shown below;"We are thrilled to announce that our EpiSwitch® NST blood test has been shown to accurately detect both #colorectalcancer and polyps. A multi-institutional study, now published in the peer-reviewed journal @Cancers_MDPI, confirms its clinical efficacy. Discussions are underway with potential partners to bring this breakthrough test to clinical practice. Read more: obdx.co/7sc'" Read more on X; @OxBioDynamics To be fair it only finished at 0.50p because of a small UT sell at 0.498p at 4.35pm Will be a big week on the back of that news and once the market digests it all Also, Unicorn fund have been selling down but now they seem to be OUT. See RNS today |
Posted at 22/10/2024 13:02 by tomboyb Logo Description automatically generatedOxford BioDynamics ("OBD" or the "Company" and, together with its subsidiaries, the "Group") EpiSwitch® CiRT Receives Clinical Approval from New York State Clinical Laboratory Evaluation Program (NYS CLEP) Oxford, UK - 22 October 2024 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on OBD's EpiSwitch® 3D genomics platform, and its partner NEXT Molecular Analytics (VA, USA) have been informed of New York State Clinical Laboratory Evaluation Program's (NYS CLEP) approval of the EpiSwitch® CiRT Test. "This is a significant milestone for any laboratory-developed test (LDT), including the CiRT test, and for the EpiSwitch platform." stated Thomas Guiel, Chief Operating Officer, "NYS CLEP is a rigorous program which bears similarities to the FDA premarket review process1. Both programs seek to mitigate the risks of harm from inaccurate and potentially unreliable LDTs. In the FDA's final ruling on LDTs earlier this year, they stated that they would not enforce their premarket review process for LDTs approved by NYS CLEP." "NYS CLEP provides an independent review of the analytical and clinical validity of any test. OBD and NEXT Molecular have been notified that the CiRT Test has passed this evaluation and been approved for clinical use." The FDA News release of 29 April 20241 states: "The FDA has also included additional enforcement discretion policies, such as for LDTs approved by the New York State's Clinical Laboratory Evaluation Program (CLEP), as described in the preamble to the final rule, where that program's review of analytical and clinical validity helps to mitigate the risk of harm from inaccurate and unreliable LDTs." 1 - FDA News Release, FDA Takes Action Aimed at Helping to Ensure the Safety and Effectiveness of Laboratory Developed Tests | FDA -Ends- |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
